Ksenia Brusilovskaya1,2,3,4,5, Philipp Königshofer1,2,3,4,5, Daniel Lampach1,2, Adrian Szodl1,2, Paul Supper1,2, David Bauer1,2,3, Andrea Beer6, Judith Stift6, Gerald Timelthaler7, Georg Oberhuber8, Bruno Karl Podesser9, Martha Seif1,2,3, Kerstin Zinober1,2,3, Nataliya Rohr-Udilova1,2,3, Michael Trauner1, Thomas Reiberger1,2,3,4,5, Philipp Schwabl1,2,3,4,5. 1. Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. 2. Vienna Hepatic Haemodynamic Lab (HEPEX), Medical University of Vienna, Vienna, Austria. 3. Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria. 4. Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria. 5. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. 6. Department of Pathology, Medical University of Vienna, Vienna, Austria. 7. The Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria. 8. INNPATH Institute for Pathology, Innsbruck, Austria. 9. Center for Biomedical Research, Medical University of Vienna, Vienna, Austria.
Abstract
BACKGROUND: In cirrhosis, the nitric oxide-soluble guanylyl cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is impaired, which contributes to increased intrahepatic vascular resistance (IHVR) and fibrogenesis. We investigated if sGC stimulation (riociguat (RIO)), sGC activation (cinaciguat (CINA)) or phosphodiesterase (PDE)-5 inhibition (tadalafil (TADA)) improves portal hypertension (PHT) and liver fibrosis. METHODS: Fifty male Sprague-Dawley rats underwent bile-duct ligation (BDL) or sham operation. RIO (0.5 mg/kg), CINA (1 mg/kg), TADA (1.5 mg/kg) or vehicle (VEH) was administered from weeks 2 to 4 after BDL. At week 4, invasive haemodynamic measurements were performed, and liver fibrosis was assessed by histology (chromotrope-aniline blue (CAB), Picro-Sirius red (PSR)) and hepatic hydroxyproline content. RESULTS: Cirrhotic bile duct-ligated rats presented with PHT (13.1 ± 1.0 mmHg) and increased IHVR (4.9 ± 0.5 mmHg⋅min/mL). Both RIO (10.0 ± 0.7 mmHg, p = 0.021) and TADA (10.3 ± 0.9 mmHg, p = 0.050) decreased portal pressure by reducing IHVR (RIO: -41%, p = 0.005; TADA: -21%, p = 0.199) while not impacting heart rate, mean arterial pressure and portosystemic shunting. Hepatic cGMP levels increased upon RIO (+239%, p = 0.006) and TADA (+32%, p = 0.073) therapy. In contrast, CINA dosed at 1 mg/kg caused weight loss, arterial hypotension and hyperlactataemia in bile duct-ligated rats. Liver fibrosis area was significantly decreased by RIO (CAB: -48%, p = 0.011; PSR: -27%, p = 0.121) and TADA (CAB: -21%, p = 0.342; PSR: -52%, p = 0.013) compared to VEH-treated bile duct-ligated rats. Hepatic hydroxyproline content was reduced by RIO (from 503 ± 20 to 350 ± 30 µg/g, p = 0.003) and TADA (282 ± 50 µg/g, p = 0.003), in line with a reduction of the hepatic stellate cell activation markers smooth-muscle actin and phosphorylated moesin. Liver transaminases decreased under RIO (AST: -36%; ALT: -32%) and TADA (AST: -24%; ALT: -27%) treatment. Hepatic interleukin 6 gene expression was reduced in the RIO group (-56%, p = 0.053). CONCLUSION: In a rodent model of biliary cirrhosis, the sGC stimulator RIO and the PDE-5 inhibitor TADA improved PHT. The decrease of sinusoidal vascular resistance was paralleled by a reduction in liver fibrosis and hepatic inflammation, while systemic haemodynamics were not affected.
BACKGROUND: In cirrhosis, the nitric oxide-soluble guanylyl cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is impaired, which contributes to increased intrahepatic vascular resistance (IHVR) and fibrogenesis. We investigated if sGC stimulation (riociguat (RIO)), sGC activation (cinaciguat (CINA)) or phosphodiesterase (PDE)-5 inhibition (tadalafil (TADA)) improves portal hypertension (PHT) and liver fibrosis. METHODS: Fifty male Sprague-Dawley rats underwent bile-duct ligation (BDL) or sham operation. RIO (0.5 mg/kg), CINA (1 mg/kg), TADA (1.5 mg/kg) or vehicle (VEH) was administered from weeks 2 to 4 after BDL. At week 4, invasive haemodynamic measurements were performed, and liver fibrosis was assessed by histology (chromotrope-aniline blue (CAB), Picro-Sirius red (PSR)) and hepatic hydroxyproline content. RESULTS: Cirrhotic bile duct-ligated rats presented with PHT (13.1 ± 1.0 mmHg) and increased IHVR (4.9 ± 0.5 mmHg⋅min/mL). Both RIO (10.0 ± 0.7 mmHg, p = 0.021) and TADA (10.3 ± 0.9 mmHg, p = 0.050) decreased portal pressure by reducing IHVR (RIO: -41%, p = 0.005; TADA: -21%, p = 0.199) while not impacting heart rate, mean arterial pressure and portosystemic shunting. Hepatic cGMP levels increased upon RIO (+239%, p = 0.006) and TADA (+32%, p = 0.073) therapy. In contrast, CINA dosed at 1 mg/kg caused weight loss, arterial hypotension and hyperlactataemia in bile duct-ligated rats. Liver fibrosis area was significantly decreased by RIO (CAB: -48%, p = 0.011; PSR: -27%, p = 0.121) and TADA (CAB: -21%, p = 0.342; PSR: -52%, p = 0.013) compared to VEH-treated bile duct-ligated rats. Hepatic hydroxyproline content was reduced by RIO (from 503 ± 20 to 350 ± 30 µg/g, p = 0.003) and TADA (282 ± 50 µg/g, p = 0.003), in line with a reduction of the hepatic stellate cell activation markers smooth-muscle actin and phosphorylated moesin. Liver transaminases decreased under RIO (AST: -36%; ALT: -32%) and TADA (AST: -24%; ALT: -27%) treatment. Hepatic interleukin 6 gene expression was reduced in the RIO group (-56%, p = 0.053). CONCLUSION: In a rodent model of biliary cirrhosis, the sGC stimulator RIO and the PDE-5 inhibitor TADA improved PHT. The decrease of sinusoidal vascular resistance was paralleled by a reduction in liver fibrosis and hepatic inflammation, while systemic haemodynamics were not affected.
Authors: Heba M Mansour; Abeer A A Salama; Rania M Abdel-Salam; Naglaa A Ahmed; Noha N Yassen; Hala F Zaki Journal: Can J Physiol Pharmacol Date: 2018-11-06 Impact factor: 2.273
Authors: Roger Flores-Costa; José Alcaraz-Quiles; Esther Titos; Cristina López-Vicario; Mireia Casulleras; Marta Duran-Güell; Bibiana Rius; Alba Diaz; Katherine Hall; Courtney Shea; Renee Sarno; Mark Currie; Jaime L Masferrer; Joan Clària Journal: Br J Pharmacol Date: 2018-01-31 Impact factor: 8.739
Authors: Hinrich C Bremer; Wolfgang Kreisel; Kai Roecker; Michael Dreher; Daniel Koenig; Anna Katharina Kurz-Schmieg; Hubert E Blum; Martin Roessle; Peter Deibert Journal: J Med Case Rep Date: 2007-07-10
Authors: Anouk Oldenburger; Gerald Birk; Marco Schlepütz; Andre Broermann; Birgit Stierstorfer; Steven S Pullen; Jörg F Rippmann Journal: Pharmacol Res Perspect Date: 2021-05
Authors: Alex Claveria-Cabello; Leticia Colyn; Iker Uriarte; Maria Ujue Latasa; Maria Arechederra; Jose M Herranz; Laura Alvarez; Jesus M Urman; Maria L Martinez-Chantar; Jesus M Banales; Bruno Sangro; Krista Rombouts; Julen Oyarzabal; Jose J G Marin; Carmen Berasain; Matias A Avila; Maite G Fernandez-Barrena Journal: Cancers (Basel) Date: 2020-12-13 Impact factor: 6.639